Iboga root is the source plant for ibogaine — but the root bark contains more than 30 alkaloids, not one. What practitioners use in ceremony, what researchers have studied, and what enters a person’s body in a therapeutic context are related but not identical. That distinction matters before deciding whether this path is appropriate for you.
Iboga root bark comes from Tabernanthe iboga, a shrub native to sub-equatorial Central Africa. The bark contains more than 30 alkaloids. Ibogaine is the most studied — roughly 50–80% of the alkaloid fraction. The rest includes ibogamine, tabernanthine, and others that are pharmacologically active but less characterised. Whole root bark used in Bwiti ceremony is a different substance from purified ibogaine HCl used in most clinical research.
What the Iboga Root Plant Is
Tabernanthe iboga is a perennial shrub that grows to roughly two metres. It is native to the rainforests of sub-equatorial Central Africa — Gabon, Cameroon, and the Democratic Republic of Congo are the primary countries where it grows wild and is cultivated.
The psychoactive alkaloids are concentrated in the root bark — the outer layer scraped from the root, not the root wood itself. When practitioners refer to "iboga root," they almost always mean root bark. It is dried and consumed in ceremony, typically in powdered form.
The plant looks unremarkable above ground: small white flowers, orange berries, dark green leaves. Its pharmacological significance bears no relationship to how ordinary it appears.
Wild iboga is increasingly scarce in Gabon and surrounding regions due to harvesting pressure. Reputable providers source root bark through documented supply chains. If a provider cannot say where their medicine comes from, that is relevant information about how they operate.
The Alkaloids in Iboga Root Bark
Iboga root bark contains more than 30 identified alkaloids. Ibogaine is the most studied, but not the only one that is pharmacologically active.
The approximate alkaloid composition of root bark:
- Ibogaine: approximately 50–80% of total alkaloid content
- Ibogamine: approximately 15%
- Tabernanthine: approximately 5%
- Remaining fraction: ibogaline, voacangine, and other minor alkaloids
These are approximations. Alkaloid concentration varies by geography, plant age, growing conditions, and harvesting method. Two samples from different regions can have meaningfully different profiles.
Ibogamine and tabernanthine are not inert. Both have documented receptor activity, though their pharmacology is less characterised than ibogaine’s. The interaction between alkaloids in whole root bark produces a different onset, duration, and phenomenology than purified ibogaine HCl. They are related substances. They are not the same substance.
Most peer-reviewed research — including the 2023 Stanford study published in Nature Medicine that documented 88% reduction in PTSD symptoms, 87% reduction in depression, and 81% reduction in anxiety at one month in 30 special operations veterans — used purified ibogaine HCl in combination with magnesium to mitigate cardiac risk. Extrapolating those numbers to whole root bark ceremony requires caution. They are not measuring the same substance.
Traditional Bwiti ceremony uses root bark. Clinical and therapeutic settings outside the Bwiti tradition typically use purified ibogaine HCl. Both approaches exist. They are not interchangeable, and the evidence base for one does not automatically transfer to the other.
How Iboga Root Has Been Used for Centuries
The Bwiti spiritual tradition of the Fang and Mitsogo peoples of Gabon and Cameroon has used iboga root bark in ceremony for centuries — long before European scientists documented its effects in the early 20th century.
Bwiti initiation ceremony typically involves large quantities of root bark consumed over a multi-day ceremonial context. These doses substantially exceed what is used in Western therapeutic settings. Bwiti initiation is a specific cultural and spiritual framework, not a therapeutic protocol. Practitioners trained within the Bwiti lineage hold ceremony differently than those trained in clinical ibogaine protocols. Both are real frameworks. They are not the same.
Howard Lotsof first documented ibogaine’s anti-addictive properties in 1962 — when he took it as a recreational substance and found that his heroin withdrawal had stopped. He spent decades attempting to bring it through clinical trials. Scheduling law in the United States placed ibogaine on Schedule I in 1970, where it remains. The fact that ibogaine research has been constrained by scheduling law for fifty years is a policy failure, not a scientific verdict. The evidence that exists — despite the obstacles — is remarkably consistent in direction.
A $50 million USD clinical trial programme is now underway involving UTMB, UTHealth Houston, Texas A&M University, and Baylor University — the direct institutional response to what the Stanford study produced and what fifty years of scheduling delay prevented.
What Iboga Root Does in the Body and Brain
Ibogaine — the primary alkaloid — acts simultaneously on four receptor systems:
- Kappa and mu-opioid receptors — interrupts opioid withdrawal, which typically stops within hours of administration
- NMDA glutamate receptors — resets the hyperactive craving circuits that sustain addiction
- Serotonin transporter — inhibits reuptake, which is the same mechanism as SSRIs and why combining them is dangerous
- Sigma-2 receptors — associated with remyelination, neural repair at the myelin level
Ibogaine also triggers GDNF (glial cell line-derived neurotrophic factor) release in the ventral tegmental area — a protein that supports survival of dopamine-producing neurons depleted by chronic addiction. BDNF (brain-derived neurotrophic factor) elevation in the prefrontal cortex supports new synaptic connections in a region that addiction consistently erodes. For a detailed account of these mechanisms, see what ibogaine does to the brain.
The active metabolite noribogaine has a half-life of 28–49 hours and remains pharmacologically active for weeks to months after ceremony. This sustained GDNF and BDNF elevation constitutes the neuroplasticity window — a period during which new patterns are more accessible and old ones less dominant. What is done in that window determines what the ceremony produces.
Integration support is not a bonus service — it determines whether the ceremony produces lasting change. The ceremony opens the window. Integration is the work done while it is open.
The ceremony was profound. The person left with clarity, reduced craving, and what felt like the beginning of something different. Six weeks later, they were back where they started — or worse, because the contrast between what had been possible and what they had returned to was now sharper. This happens when people return to the same environment, the same relationships, and the same unaddressed conditions that produced the problem in the first place. The window does not stay open indefinitely.
One cardiac effect requires direct mention: ibogaine prolongs the QT interval in all cases. This is not a rare adverse event — it is the expected pharmacological response. It is why continuous ECG monitoring and a pre-ceremony EKG are non-negotiable. The EKG identifies cardiac contraindications before ceremony. Not during it.
Who This Is Not For
Iboga root — whether as whole root bark or purified ibogaine HCl — has absolute contraindications. These do not change based on provider, context, or dose.
Absolute contraindications:
- QT prolongation, significant cardiac arrhythmia, or recent myocardial infarction — identified by pre-ceremony EKG, required without exception at any legitimate provider
- Severe liver or kidney disease — ibogaine is metabolised hepatically; impaired clearance amplifies all risks
- Active psychosis or schizophrenia spectrum disorder
- Current SSRIs or SNRIs without a completed supervised taper — serotonin syndrome risk is real and potentially fatal, and no case is an exception to this rule
- Methadone — a supervised transition protocol is required before ibogaine is safe
- Lithium and certain other psychiatric medications
- Pregnancy
Any provider offering ibogaine ceremony without a mandatory EKG is not operating safely. Full stop. The cardiac risk is not theoretical. QT prolongation is the mechanism of documented ibogaine-related fatalities. The EKG is what identifies it before ceremony, not during.
Beyond the medical list: someone in acute psychiatric crisis is not an appropriate candidate. Ibogaine amplifies what is present. Entering ceremony in a state of acute instability does not produce stability.
Someone primarily seeking a mystical experience, a shortcut to insight, or an intense psychedelic encounter is also not an appropriate candidate. Iboga tends to show people what they have been avoiding. The most consistent observation across practitioners is that the medicine does not deliver what people hope for — it delivers what they need, which is often not the same thing. People who arrive with expectations the medicine does not serve tend to leave disappointed, sometimes disoriented.
For the complete clinical list, see the ibogaine contraindications guide.
Is This Right for You?
Iboga root ceremony — within the Bwiti tradition or in a modern therapeutic context using purified ibogaine — is not appropriate for most people. It requires medical screening, no absolute contraindications, and a genuine willingness to encounter what the medicine produces rather than what you came hoping for.
The people who get the most from this work are typically not people seeking it as a first option. They have tried other approaches — therapy that circled without landing, medications that blunted rather than resolved, abstinence that held for months and then did not. By the time they arrive, they have evidence that conventional approaches are not enough. That history tends to produce people who are genuinely ready for what iboga shows them.
If you are in active psychiatric crisis, currently on SSRIs or SNRIs without a completed taper, on methadone without a transition protocol, or have cardiac conditions that have not been assessed — ibogaine is not the right path at this moment. These are not soft disqualifiers. They are the conditions under which ceremony becomes dangerous.
If you want to understand whether iboga ceremony at Transcend in Vancouver is appropriate for your specific situation, the starting point is the application. Every application receives a personal response within 2–3 business days. The intake conversation will address your history and circumstances directly — not to sell you on a ceremony, but to determine whether one is appropriate.
Ibogaine ceremony at Transcend costs $2,000–$5,000 CAD. This includes the on-site medical professional, continuous cardiac monitoring throughout the 12–24 hour active experience, the medicine, and facilitation. Integration coaching is available separately at $150–$300 CAD per session in packages of three or more.
Further reading: What ibogaine does to the brain · What to expect at an ibogaine treatment centre · Ibogaine success rates — what the research shows · Ibogaine treatment for special operations veterans / Nature Medicine (2023) · Ibogaine compound data / PubChem